In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

PowderJect acquires Celltech Medeva's vaccine business

Executive Summary

PowderJect Pharmaceuticals (needle-free injection systems) will acquire the vaccines business of Celltech Group's Medeva subsidiary for about $79mm (UK55mm) plus a potential earn-out payment of about UK2mm, dependent on sales levels of Medeva's Fluvirin influenza vaccine for the year 2000 season.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Intra-Biotech Deal

Related Companies

UsernamePublicRestriction

Register